| Row | STUDYID | DOMAIN | ETCD | ELEMENT | TESTRL | TEENRL | TEDUR |
|---|
| 1 | EX2 | TE | SCRN | Screen | Informed consent | 2 weeks after start of Element | P14D |
| 2 | EX2 | TE | PUSL | PlaceboUSUAL | First dose of a treatment study product Epoch, where dose is placeboproduct is the usual tobacco product | 2 weeks after start of Element | P14D |
| 3 | EX2 | TE | 5TPA5 mg | TP A | First dose of a treatment study product Epoch , where dose is 5 mg drugtobacco product A | 2 weeks after start of Element | P14D |
| 4 | EX2 | TE | 10TPB10 mg | TP B | First dose of a treatment study product Epoch, where dose is 10 mg drugtobacco product B | 2 weeks after start of Element | P14D |
| 5 | EX2 | TE | REST | Rest | 48 hrs after last dose of preceding treatment study product Epoch | 1 week after start of Element | P7D |
| 6 | EX2 | TE | FU | Follow-up | 48 hrs after last dose of third treatment study product Epoch | 3 weeks after start of Element | P21D |